tbuckley/cabot-search huggingface dataset:
Markers of Inflammation and Coagulation after Long-Term Exposure to Coarse Particulate Matter: A Cross-Sectional Analysis from the Multi-Ethnic Study of Atherosclerosis
Authors: Sara D. Adar, Jennifer D’Souza, Kari Mendelsohn-Victor, David R. Jacobs, Mary Cushman, Lianne Sheppard, Peter S. Thorne, Gregory L. Burke, Martha L. Daviglus, Adam A. Szpiro, Ana V. Diez Roux, Joel D. Kaufman, Timothy V. Larson
Journal: Environmental Health Perspectives (2015)

Toxicological research suggests that coarse particles (PM10-2.5) are inflammatory, but responses are complex and may be best summarized by multiple inflammatory markers. Few human studies have investigated associations with PM10-2.5 and, of those, none have explored long-term exposures. Here we examine long-term associations with inflammation and coagulation in the Multi-Ethnic Study of Atherosclerosis.Participants included 3,295 adults (45-84 years of age) from three metropolitan areas. Site-specific spatial models were used to estimate 5-year concentrations of PM10-2.5 mass and copper, zinc, phosphorus, silicon, and endotoxin found in PM10-2.5. Outcomes included interleukin-6, C-reactive protein, fibrinogen, total homocysteine, D-dimer, factor VIII, plasmin-antiplasmin complex, and inflammation and coagulation scores. We used multivariable regression with multiply imputed data to estimate associations while controlling for potential confounders, including co-pollutants such as fine particulate matter.Some limited evidence was found of relationships between inflammation and coagulation and PM10-2.5. Endotoxin was the PM10-2.5 component most strongly associated with inflammation, with an interquartile range (IQR) increase (0.08 EU/m3) associated with 0.15 (95% CI: 0.01, 0.28; p = 0.03) and 0.08 (95% CI: -0.07, 0.23; p = 0.28) higher inflammation scores before and after control for city, respectively. Copper was the component with the strongest association with coagulation, with a 4-ng/m3 increase associated with 0.19 (95% CI: 0.08, 0.30; p = 0.0008) and 0.12 (95% CI: -0.05, 0.30; p = 0.16) unit higher coagulation scores before and after city adjustment, respectively.Our cross-sectional analysis provided some evidence that long-term PM10-2.5 exposure was associated with inflammation and coagulation, but associations were modest and depended on particle composition.
Abstract 970: Multi-layer and integrative analysis of the whole transcriptome in Asian gastric cancer: AMPKβ modulation in cancer progression
Authors: Yon Hui Kim, Han Liang, Xiuping Liu, Julie Izzo, Robert Lemos, Ju-Seog Lee, Jae Yong Cho, Jae Ho Cheong, Hoguen Kim, Min Li, Thomas J. Downey, Matthew D. Dyer, Yongming Sun, Jingtao Sun, Ellen M. Beasley, Hyun Cheol Chung, Sung Hoon Noh, John N. Weinstein, Chang-gong Liu, Garth Powis
Journal: Cancer Research (2012)

Abstract We performed whole-transcriptome profiling of gastric cancer_the most common cancer in developing countries and the second leading cause of cancer deaths in the world. Applying a innovative SOLiD RNA-Seq approach to 24 gastric tumor samples and 6 noncancerous samples, we generated 3.0 billion short reads to quantitatively measure the abundance of mRNAs and small non-coding RNAs. We then developed a multi-layer analysis to identify differentially expressed mRNAs and microRNAs, and novel single-nucleotide mutations candidates associated with gastric cancer. With the insights from the multi-layer analysis, we experimentally demonstrated a critical role for AMPKβ modulation in gastric cancer progression. This work provides a multi-faceted portrait of the Asian gastric cancer transcriptome, which facilitates the elucidation of molecular mechanisms of gastric carcinogenesis and the development of targeted therapies. By integrating data obtained on the expression of both mRNa and miRNa molecules, we were able to identify certain gene signatures uniquely expressed in gastric cancer. This gene signatures along with gastric cancer-related therapeutic target gene signature, showed molecular changes as robust biological markers. Integration of differentially expressed mRNAs and microRNA profiles allowed us to identify potential miRNA drivers of disease progression. We demonstrated the translational relevance of AMPKβ as a potential therapeutic target for treatment and for prediction of early stage gastric cancer. This work lays a critical foundation for the identification of molecular mechanisms of gastric carcinogenesis and the development of related targeted therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 970. doi:1538-7445.AM2012-970
WT1 PEPTIDE VACCINATION FOR MALIGNANT GLIOMAS AS A PART OF MULTI-MODAL THERAPY
Authors: N. Hashimoto, A. Tsuboi, Y. Chiba, R. Hirayama, K. Takano, N. Kijima, Y. Oka, N. Kagawa, S. Izumoto, H. Sugiyama, T. Yoshimine
Journal: Neuro-Oncology (2014)

BACKGROUND: We have been conducting clinical trials of peptide vaccination targeting WT1 gene product against malignant gliomas. Given the results of phase II trial for recurrent malignant gliomas (Izumoto, Hashimoto et al., J Neurosurg 2008), we performed recursive partitioning analyses (RPA) (Carson et al., J Clin Oncol, 2007). We have also completed phase I trial of combined temozolomide (TMZ) and WT1 vaccination for newly diagnosed glioblastomas (GBM). METHODS: After the Kaplan-Meier analyses giving median PFS and OS, 70 patients with recurrent gliomas who entered into the phase II trial were classified into RPA classes, following Carson et al. Seven patients were enrolled into phase I study for newly diagnosed GBM. They underwent combined TMZ and WT1 vaccination just after the initial RT/TMZ. In both studies, immunological response was analyzed on WT1-specific T cells induction in peripheral blood, delayed type hypersensitivity as well as intra-tumoral immune cell analysis when surgery was indicated after vaccination. In the phase II study, predictive or prognostic indicators were extensively investigated. Although we have originally used RECIST criteria for MRI evaluation, we tried to directly compare RECIST, Macdonald, RANO and irRC using datasets from 50 GBM patients in terms of survival prediction. RESULTS: Median OS in 7 classes (I to VII) obtained by RPA showed the same tendency for OS ranking, and 6 of 7 classes (class II to VII) presented longer OS as compared with Carsons. Hazard ratio calculated for WT1 vaccination was 0.372, which was better than those with other agents used in previously published phase I/II studies. Seven patients with combined TMZ and WT1 vaccination tolerated well and showed no adverse events above CTCAE grade III, except for grade III lymphocytopenia in 71.4% of patients possibly due to preceded RT/TMZ therapy. PFS ranged from 5.2 to 37.1 months (median 31.5 months). We have confirmed the induction of WT1 specific T cells in the majority of patients of both studies. Patients showed longer survival statistically, who had stronger expression of WT1 protein on the tumor cells, DTH turning to be positive and methionine uptake decreased within 3 months. An evaluation by RANO was statistically correlated best with OS among those 4 criteria. CONCLUSIONS: Multivariate analysis with RPA showed the efficacy of WT1 vaccination with some predictive indicators. The following phase I study revealed the safe combination of TMZ and WT1, and throw light on the new multi-modal strategy. SECONDARY CATEGORY: Clinical Neuro-Oncology.
Stimulation of Gastric Secretion and Gastrin Release by Single Oral Doses of Calcium Carbonate in Man
Authors: Jonathan A. Levant, John H. Walsh, Jon I. Isenberg
Journal: New England Journal of Medicine (1973)

In 13 fasting men with and without duodenal ulcer, oral administration of 2 g of calcium carbonate produced a significant increase (p<0.025) in gastric acid secretion above basal levels for two hours. Serum gastrin concentration increased significantly (p<0.05) 30 and 60 minutes after administration of 2 g of calcium carbonate. No significant change in acid secretion or serum gastrin occurred after oral administration of 2 g of sodium bicarbonate. In additional tests, a significant increase (p<0.05) in acid secretion occurred in each of five subjects given 0.5 g of calcium carbonate by mouth. Single oral doses of calcium carbonate thus appear capable of stimulating gastric acid secretion and gastrin release in fasting subjects with and without duodenal ulcer. (N Engl J Med 289:555–558, 1973)
Abstract LB-364: Dovitinib (TKI258), a multikinase inhibitor of FGFR, PDGFR, and VEGFR tyrosine kinases, induces growth suppression in mouse models of human hepatocellular carcinoma (HCC)
Authors: Hung T. Huynh, Pierce Chow, Chee Khee Soo, Micheal Shi
Journal: Cancer Research (2010)

Abstract Background: Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) and their receptors are over-expressed and involved in the neovascularization, invasiveness, and metastatic potential of HCC. Therefore, suppression of the VEGFR/FGFR/PDGFR by TKI258 may represent a novel approach for treatment of HCC. The aims of this study were 1) to determine the in vivo antineoplastic activity of dovitinib (TKI258), a multikinase inhibitor of FGF, VEGF, and PDGF signaling pathways, and 2) to compare the efficacy of TKI258 with sorafenib in mouse models of human HCC. Experimental Design: We treated six patient-derived HCC xenografts with i) 50 or 75 mg/kg TKI258 and ii) 50 mg/kg sorafenib. Western blotting was employed to determine pharmacodynamic changes in biomarkers relevant to FGF/VEGF/PDGF signaling pathways. Apoptosis, microvessel density, and cell proliferation were analyzed by immunohistochemistry. Results: Body weight was maintained up to 75 mg/kg TKI258 and 50 mg/kg sorafenib. TKI258 treatment resulted in suppression of tumor growth in a dose-dependent manner. Potent antitumor activity was observed in all six HCC xenograft lines studied. The T/C ratio's for 50 mg/kg TKI258 and 50 mg/kg sorafenib for xenograft lines 06-0606, 26-0808A, 26-1004, 28-1108, 5-1318, and 25-0705A, were 0.04 and 0.22; 0.11 and 0.18; 0.13 and 0.26; 0.23 and 0.37; 0.14 and 0.30, and 0.28 and 0.19, respectively, suggesting that in general the antitumor effect of TKI258 was greater than that of sorafenib. TKI258-induced growth inhibition was associated with inhibition of angiogenesis and cell proliferation and induction of tumor cell death. Inhibition of p-FGFR, p-PDGFR, p-VEGFR-2, p-ERK1/2, and upregulation of Bim and p-histone H2A-X Ser139 were observed. Conclusion: TKI258 demonstrated significant antitumor effect in a mouse model of human HCC xenograft. This study provides a strong rationale for clinical investigation of TKI258 in patients with HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-364.
P295 Patients' Preference Of Established And Emerging Treatments For Obstructive Sleep Apnoea
Authors: T. Campbell, M. Pengo, R. Brown, A. Birdseye, K. Bacon, J. Steier
Journal: Thorax (2014)

<h3>Background</h3> Obstructive sleep apnoea (OSA) is the most common form of sleep-disordered breathing, and the standard treatment is continuous positive airway pressure (CPAP). Emerging treatments for OSA, including electrical hypoglossal nerve stimulation (HNS) and non-invasive electrical stimulation (nES), are currently being developed. To involve patients in the development of research projects, we evaluated patients’ preference for different treatments of OSA using a short survey. <h3>Patients and methods</h3> We recorded patients’ age, gender, body-mass-index (BMI), Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ10), severity of OSA, and current treatment. We showed pictures of existing (CPAP, mandibular advancement device (MAD)) and emerging treatments (HNS and nES). We then asked 1) whether they were interested in further information about HNS/nES, 2) if they would be willing to try HNS/nES, and 3) if they were to choose only one of the four listed treatments, which one would they prefer to use every night. <h3>Results</h3> 162 patients completed the survey (81 males, mean age 52 (12) years, BMI 34 (7.3) kg/m<sup>2</sup>, ESS 10.2 (6.0) points, FOSQ10 28.5 (8.1) points). The majority of the respondents (89.5%) had been diagnosed with OSA, with 95.4% of those being treated with CPAP. 91.3% of the respondents were interested in more information and were willing to try HNS/nES. Most respondents preferred the potential use of nES (56.7%), while 21.7% chose HNS, 17.8% CPAP, and 3.8% the MAD. There were no differences in the characteristics of the patients who preferred nES compared to those who preferred other treatments; however, a regression analysis showed that a low ESS score was a predictor of patients choosing nES (p &lt; 0.05). <h3>Conclusion</h3> Although the CPAP is the established treatment for OSA, most patients would prefer alternatives for long-term treatment. The majority of the respondents were interested in emerging technologies, with less sleepy patients more likely to choose less invasive treatment options.
AB0625 Effect of one cycle of rituximab in the lipid profile of patients with refractory systemic lupus erythematosus (SLE):
Authors: L. Nieves-Martín, J.M. Pego, J.L. Marenco, L. Carreño, M. Galindo, E. Tomero, I. Rúa-Figueroa, B.E. Hernández, J. Narváez, E. Úcar, A. Olivé, A. Zea, M. Fernández-Castro, E. Raya-Άlvarez, M. Freire, V.M. Martínez-Taboada, J. Pérez-Venegas, A.I. Sánchez-Atrio, I. Villa, S. Manrique-Arija, V. Rodríguez-García, C. Romero-Barco, F.J. Lόpez-Longo, P.E. Carreira, R. Martínez Pérez, R. García-Vicuña, A. Fernández-Nebro
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To investigate lipidic changes that occurs with Rituximab(RTX) in refractory SLE-patients. <h3>Methods</h3> Multicenter, retrospective, longitudinal study. All SLE-patients from LESIMAB study with basic lipid data at baseline and 6±3 months after the first cycle of RTX were included. Cardiovascular risk factors (CVRF), comorbidities and treatments were collected, including lipid profile. <h3>Results</h3> 101 patients were included (91% women; age 38.7±12.1yrs). The duration of SLE was 7.1±6.1yrs, median of severe organ-systems affected was 2.0 (range, 0-6), and median of previous drugs against SLE was 5 (range, 2-9). The Charlson-age comorbidity index was of 2.0±1.2 and the number of classic CVRF was 1.1±0.1. The baseline SLEDAI was 14.2±9.6. RTX was administrated with other drugs, including corticosteroids (n=101), hydroxychloroquine (HCQ; n=48), and statins (n=16). As it shows the table, the mean of lipid profile at baseline was good and these values were similar between patients with concomitant HCQ. The patients who were receiving statins had worse baseline lipid profile (CT, p=0.028; LDL, p=0.011; VLDL, p=0.040; TG, p=0.040).After 6±3 months of RTX treatment, the global lipids values didn't change significantly (Table). However, the patients who achieved a good clinical response (partial or complete) in the SLE activity their lipid profile also improved [TC (p=0.004), HDL (p=0.004), VLDL (p=0.041) and TG (p=0.041)] and a correlation between improvement of SLEDAI (delta-SLEDAI at 24w from baseline, 9.8±9.5) and the improvement of the lipid profile after 24w was observed: delta-CT 24w (r=0,349; p&lt;0,001), delta-TG 24w (r=0,366; p&lt;0,001) y delta-VLDL 24w (r=0,366; p&lt;0,001). Although the needs of corticosteroids decreased (delta-prednisone after 24w was 21.0±63.8mg/d), it didn't influence in the lipid improvement, since there was no correlation between delta-prednisone after 24w and improvement in lipid profile. <h3>Conclusions</h3> RTX doesn't seem to have an intrinsic effect in the lipid profile from patients with refractory SLE. However, a good control of the disease activity promotes a improvement in lipid profile. <h3>Disclosure of Interest</h3> None Declared
The Relation between Universal Health Insurance and Cost Control
Authors: M A Goldberg, T R Marmor, J White
Journal: New England Journal of Medicine (1995)

The failure of national health care reform in 1994 had too many causes to list. But surely one was doubt that costs could be controlled and coverage expanded simultaneously. That doubt became the fear that most Americans would lose as a result of reform. That fear, however, was based on a misconception of the workings of our health care system. In fact, cost control and universal coverage not only can be combined, but they should be. Last year's failure was unnecessary as well as tragic.Every nation whose economic level approaches that of the United States ensures broad health coverage . . .
Abstract 855: Medication use and ovary cancer risk in the California Teachers Study
Authors: Lei Duan, James Lacey, Christina Clarke-Dur, Dee West, Leslie Bernstein, Katherine Henderson
Journal: Cancer Research (2010)

Abstract Background: Approximately 21,000 new cases of ovarian cancer are diagnosed in the United States each year. Because inflammation is thought to affect ovarian carcinogenesis, non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, and other medications such as acetaminophen and histamine receptor antagonists, may affect the risk of ovarian cancer. However, existing epidemiological evidence on these associations is mixed. Methods: We assessed the relationship between medication use and risk of invasive epithelial ovarian cancer in the California Teachers Study (CTS), a prospective cohort of former or current female public school teachers and administrators in California. Analysis included 104,184 women, of whom 420 were diagnosed with invasive epithelial ovarian cancer during follow-up through December 31, 2007. Self-reported medication use from the baseline CTS questionnaire (1995-1996) was used to classify exposures. Relative risks (RR) and 95% confidence intervals (CI) were obtained using Cox proportional hazards methods. Results: Regular use, defined as at least once a week, of aspirin (RR 0.96; 95%CI 0.76 − 1.19), non-aspirin NSAIDs (RR 1.04; 95%CI 0.80 − 1.30), acetaminophen (RR 1.13; 95%CI 0.85 − 1.50) or histamine receptor antagonists (RR 0.85; 95%CI 0.58 − 1.20) was not associated with ovarian cancer risk. Ovarian cancer risk was not associated with daily use of aspirin (RR 1.04; 95%CI 0.77 − 1.45) or non-aspirin NSAIDs (RR 0.85; 95%CI 0.56 − 1.31) but was associated with daily use of acetaminophen (RR 1.82, 95%CI 1.01 − 2.95), and the latter association persisted after excluding ovarian cancers diagnosed during the first one to five years of follow-up. Two-thirds of the daily acetaminophen users also reported using acetaminophen for more than three years, but there was no association between increasing duration of use and ovarian cancer risk. Conclusion: Our results do not support the hypothesis that these medications reduce the risk of ovarian cancer. Conversely, the finding that daily acetaminophen use was associated with increased risk of ovarian cancer differs from previous studies and may warrant further investigation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 855.
A case of Good syndrome with refractory gastrointestinal ulcers
Authors: Y. Nakagawa, K. Murakami, Y. Hirashita, R. Ogawa, A. Hisamatsu, K. Mizukami, M. Uchida, T. Okimoto, M. Kodama, S. Urabe, K. Kashima, T. Fujioka
Journal: Endoscopy (2012)

A 61-year-old woman was referred to our hospital in November 2011 for treatment of chronic diarrhea and refractory gastrointestinal ulcers. Her medical history included thymoma (resected at age 44) accompanied by hypogammaglobulinemia and pure red cell aplasia (PRCA), and a distal gastrectomy for gastric ulcer (refractory to proton pump inhibitor treatment and Helicobacter pylori eradication).
A PSYCHOLOGICAL STUDY OF A 106-YEAR-OLD-MAN
Authors: DANIEL B. SCHUSTER
Journal: American Journal of Psychiatry (1952)

1. A case of a superannuated man, free of dementia despite his advanced age, is presented to illustrate that there is not necessarily a direct relationship between age and dementia. This man, on detailed study, was found to have high intellectual endowment and good emotional resources. 2. Dynamic concepts of aging are discussed and the speculation presented that strong ego resources may play a role in resisting the onset of dementia in advancing age.
FRI0470 Comparative Study of Infliximab versus Adalimumab in Patients with Refractory Uveitis Due to BehÇEt's Disease. Multicenter Study of 125 Cases
Authors: E. Beltrán-Catalán, V. Calvo-Río, P. Rodríguez-Cundin, R. Blanco-Alonso, J. Sánchez-Bursόn, M. Mesquida, A. Adán, M.V. Hernandez, M. Hernandez Garfella, L. Martínez-Costa, A. Sellas, M. Cordero Coma, M. Díaz-Llopis, J.L. García Serrano, N. Ortego, J.M. Herreras, A. Fonollosa, Ά.M. García-Aparicio, O. Maíz, A. Blanco, I. Torre, C. Fernández-Espartero, V. Jovaní, D. Peiteado, E. Pato-Cour, J. Cruz, E. Aurrecoechea, M. García, M.A. Caracuel, C. Montilla, A. Atanes, F. Francisco, S. González, M.A. González-Gay
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To compare the efficacy and safety of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet9s disease (BD) for 1-year period. <h3>Methods</h3> Multicenter study of 125 patients with BD9s uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. IFX (3-5 mg/kg at 0, 2, and 6 weeks and then every 4-8 weeks) was used in 75 cases and ADA (usually 40 mg every 2 weeks) in 50 cases. The main comparative outcome measures were improvement of visual acuity (VA) (at least 20%), complete inactivity of anterior chamber inflammation, vitritis, and retinal vasculitis as well as macular thickness &lt;250 microns. A bivariate and logistic regression analysis was performed for every previous outcome between ADA vs IFX (SPSS20.0 package). <h3>Results</h3> 125 patients (223 affected eyes) were studied. No statistically significant differences at baseline were observed between IFX vs ADA groups in sex (♂/♀; 41/34 vs 29/21; p=0,71), mean age (39,2±9.39 vs 36,14±12,7; p=0.12), HLA B51 positive (75% vs 75%), uveitis duration before anti TNF-α onset (median [IQR]; 36 [12-71] vs 24 months [12-60]; p=0.4), VA (0,47±0,26 vs 0,52±0,27; p=0,29), anterior chamber cells (median [IQR]; 0,5 [0-2] vs 1,5 [0-2]; p=0,2), retinal vasculitis (73,2% vs 75%; p=0,95); macular thickness (285,90±90,15 vs 312,02±106,57; p=0,25), combined treatment (82.7% vs 77,6%; p=0.481), basal degrees of immunosuppression (mean ± SD; 11.35±5.67 vs 9.65±4.68; p=0.09). There were a better non-statistical respond with ADA in improvement of VA, complete inactivity of anterior chamber inflammation, and macular thickness &lt;250 microns, and with IFX in inactivity of vitritis, and retinal vasculitis (Table) <h3>Conclusions</h3> Our study suggests that ADA and IFX do not show statistical differences at one year in refractory uveitis of BD. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4766
MULTIMODALITY INTRAVASCULAR IMAGING TO EVALUATE GENDER DIFFERENCES IN PLAQUE MORPHOLOGY IN STABLE CORONARY ARTERY DISEASE
Authors: Aditya S. Bharadwaj, Yuliya Vengrenyuk, Jacobo Pena, Takahiro Yoshimura, Safwan Kezbor, Jason Kovacic, Usman Baber, Hasan Choudury, Joseph Sweeny, Srinivas Kesanakurthy, Jagat Narula, Samin Sharma, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2016)